A phase 2 clinical trial is currently in processing for patients with T-cell lymphomas (including ENKTL) to determine the effect of brentuximab vedotin on CD30-positive cases [25]. This evidence concerns the gene TNFRSF8 and T-cell non-Hodgkin lymphoma.